Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention

Why It Matters

The stock’s deep discount and strong dividend provide a compelling entry point for value‑oriented investors if the oral GLP‑1 gains market share, potentially reshaping the competitive dynamics of the weight‑loss drug market.

Key Takeaways

• Novo's stock down 66% from 2024 highs.
• GLP‑1 pill launch gives Novo first-mover advantage.
• P/E 13.5 vs Lilly's 45; dividend yield 3.7%.
• 2026 guidance weak, revenue expected decline.
• Aggressive pipeline updates aim to regain market share.

Pulse Analysis

The GLP‑1 market has become a battleground for pharmaceutical giants, with obesity and diabetes treatments driving unprecedented demand. Eli Lilly’s injectable offerings, Mounjaro and Zepbound, have captured headlines, but Novo Nordisk’s early entry into the space gave it a reputation as an innovator. As the market matures, patient preference is shifting toward more convenient delivery methods, creating an opening for oral formulations to expand the overall addressable pool. Novo’s pill, launched ahead of Lilly’s, could convert hesitant patients and increase total GLP‑1 utilization, a factor investors are watching closely.

From a valuation perspective, Novo Nordisk appears markedly cheaper than its U.S. counterpart. A price‑to‑earnings multiple near 13.5 contrasts sharply with Lilly’s 45, while Novo’s 3.7% dividend yield—backed by a 40% payout ratio—offers tangible income in a low‑rate environment. These metrics suggest a margin of safety for investors seeking both yield and upside. The company’s recent pricing agreement with the U.S. government, however, tempers earnings expectations for 2026, underscoring the importance of balancing short‑term guidance against long‑term growth prospects.

Looking ahead, Novo’s strategy hinges on scaling the oral GLP‑1 product and refreshing its injectable pipeline to stay competitive. If the pill gains traction, it could not only boost Novo’s top line but also pressure rivals to accelerate their own oral developments. Nevertheless, execution risks remain, including manufacturing constraints and regulatory hurdles. For dividend‑focused and contrarian investors, the combination of an attractive valuation, solid dividend, and potential market share gains makes Novo Nordisk a stock worth monitoring as the GLP‑1 landscape evolves.